Molecular Cancer,
Journal Year:
2025,
Volume and Issue:
24(1)
Published: Jan. 18, 2025
Clinically,
multimodal
therapies
are
adopted
worldwide
for
the
management
of
cancer,
which
continues
to
be
a
leading
cause
death.
In
recent
years,
immunotherapy
has
firmly
established
itself
as
new
paradigm
in
cancer
care
that
activates
body's
immune
defense
cope
with
cancer.
Immunotherapy
resulted
significant
breakthroughs
treatment
stubborn
tumors,
dramatically
improving
clinical
outcome
patients.
Multiple
forms
immunotherapy,
including
checkpoint
inhibitors
(ICIs),
adoptive
cell
therapy
and
vaccines,
have
become
widely
available.
However,
effectiveness
these
immunotherapies
is
not
much
satisfying.
Many
patients
do
respond
disease
recurrence
appears
unavoidable
because
rapidly
evolving
resistance.
Moreover,
can
give
rise
severe
off-target
immune-related
adverse
events.
Strategies
remove
hindrances
mainly
focus
on
development
combinatorial
or
exploitation
novel
immunotherapeutic
mediations.
Nanomaterials
carrying
anticancer
agents
target
site
considered
practical
approaches
treatment.
Nanomedicine
combined
offers
possibility
potentiate
systemic
antitumor
immunity
facilitate
selective
cytotoxicity
against
cells
an
effective
safe
manner.
A
myriad
nano-enabled
currently
under
investigation.
Owing
gaps
between
preclinical
studies,
nano-immunotherapy
faces
multiple
challenges,
biosafety
nanomaterials
trial
design.
this
review,
we
provide
overview
summarize
evidence
indicating
how
nanomedicine-based
increase
efficacy
immunotherapies.
We
also
discuss
key
challenges
emerged
era
nanotechnology-based
immunotherapy.
Taken
together,
combination
drawing
increasing
attention,
it
anticipated
will
achieve
desired
success
therapy.
Advanced Healthcare Materials,
Journal Year:
2021,
Volume and Issue:
11(5)
Published: June 24, 2021
Over
the
past
decades,
lipid-based
nanoparticle
drug
delivery
systems
(DDS)
have
caught
attention
of
researchers
worldwide,
encouraging
field
to
rapidly
develop
improved
ways
for
effective
delivery.
One
most
prominent
examples
is
liposomes,
which
are
spherical
shaped
artificial
vesicles
composed
lipid
bilayers
and
able
encapsulate
both
hydrophilic
hydrophobic
materials.
At
same
time,
biological
nanoparticles
naturally
secreted
by
cells,
called
extracellular
(EVs),
emerged
as
promising
more
complex
biocompatible
DDS.
In
this
review
paper,
differences
similarities
in
composition
evaluated,
critical
mediators
that
affect
their
pharmacokinetics
elucidate.
Different
strategies
been
assessed
tweak
liposomes
EVs
explored,
detailing
effects
on
circulation
targeting
capacity,
cytoplasmic
therapeutic
cargo.
Finally,
whether
a
hybrid
system,
consisting
combination
only
constituents
vesicles,
could
offer
best
worlds
discussed.
Through
these
topics,
novel
leads
further
research
provided
and,
importantly,
gain
insight
what
liposome
EV
can
learn
from
each
other.
Molecules,
Journal Year:
2023,
Volume and Issue:
28(18), P. 6624 - 6624
Published: Sept. 14, 2023
Knowing
the
beneficial
aspects
of
nanomedicine,
scientists
are
trying
to
harness
applications
nanotechnology
in
diagnosis,
treatment,
and
prevention
diseases.
There
also
potential
uses
designing
medical
tools
processes
for
new
generation
scientists.
The
main
objective
conducting
this
research
review
is
gather
widespread
nanomedicine
under
one
heading
highlight
standard
practices
field.
Comprehensive
has
been
conducted
incorporate
latest
data
related
medicine
therapeutics
derived
from
acknowledged
scientific
platforms.
Nanotechnology
used
conduct
sensitive
procedures.
showing
successful
fields
diagnostics,
disease
regenerative
medicine,
gene
therapy,
dentistry,
oncology,
aesthetics
industry,
drug
delivery,
therapeutics.
A
thorough
association
cooperation
between
physicians,
clinicians,
researchers,
technologies
will
bring
forward
a
future
where
there
more
calculated,
outlined,
technically
programed
field
nanomedicine.
Advances
being
made
overcome
challenges
associated
with
application
due
pathophysiological
basis
This
highlights
multipronged
how
proving
health
industry.
need
minimize
health,
environmental,
ethical
concerns
linked
nanotechnology.
Pharmaceutics,
Journal Year:
2020,
Volume and Issue:
12(9), P. 837 - 837
Published: Sept. 1, 2020
Nanotechnologies
have
attracted
increasing
attention
in
their
application
medicine,
especially
the
development
of
new
drug
delivery
systems.
With
help
nano-sized
carriers,
drugs
can
reach
specific
diseased
areas,
prolonging
therapeutic
efficacy
while
decreasing
undesired
side-effects.
In
addition,
recent
nanotechnological
advances,
such
as
surface
stabilization
and
stimuli-responsive
functionalization
also
significantly
improved
targeting
capacity
nanocarrier
assisted
system.
this
review,
we
evaluate
advances
different
nanocarriers
applications
therapeutics
delivery.
Acta Pharmaceutica Sinica B,
Journal Year:
2021,
Volume and Issue:
11(8), P. 2265 - 2285
Published: March 24, 2021
The
administration
of
nanoparticles
(NPs)
first
faces
the
challenges
evading
renal
filtration
and
clearance
reticuloendothelial
system
(RES).
After
that,
NPs
infiltrate
through
expanded
endothelial
space
penetrated
dense
stroma
tumor
microenvironment
to
cells.
As
long
as
possible
prolong
time
remaining
in
tissue,
release
active
agent
induce
pharmacological
action.
This
review
provides
a
comprehensive
summary
physical
chemical
properties
influence
various
biological
factors
microenvironment,
discusses
how
improve
final
efficacy
adjusting
characteristics
structure
NPs.
Perspectives
future
directions
are
also
provided.
Molecules,
Journal Year:
2020,
Volume and Issue:
25(11), P. 2692 - 2692
Published: June 10, 2020
RNA
interference
(RNAi)
uses
small
interfering
RNAs
(siRNAs)
to
mediate
gene-silencing
in
cells
and
represents
an
emerging
strategy
for
cancer
therapy.
Successful
RNAi-mediated
gene
silencing
requires
overcoming
multiple
physiological
barriers
achieve
efficient
delivery
of
siRNAs
into
vivo,
including
tumor
and/or
host
the
micro-environment
(TME).
Consequently,
lipid
polymer-based
nanoparticle
siRNA
systems
have
been
developed
surmount
these
barriers.
In
this
article,
we
review
strategies
that
facilitate
survival
circulatory
system,
movement
from
blood
tissues
TME,
targeted
or
specific
cell
types,
cellular
uptake,
escape
endosomal
degradation.
We
also
discuss
use
various
types
carriers
therapy,
a
section
on
anti-tumor
nanovaccines
enhanced
by
siRNAs.
Finally,
current
recent
clinical
trials
using
NPs
loaded
with
The
therapeutics
field
is
rapidly
evolving,
it
conceivable
precision
therapy
could,
relatively
near
future,
benefit
combined
therapies,
example
immune
checkpoint
blockade
together
gene-targeting
siRNAs,
personalized
enhancing
fine-tuning
patient’s
therapeutic
response.
Journal of Extracellular Vesicles,
Journal Year:
2020,
Volume and Issue:
9(1)
Published: Aug. 19, 2020
A
long-term
and
huge
challenge
in
nanomedicine
is
the
substantial
uptake
rapid
clearance
mediated
by
mononuclear
phagocyte
system
(MPS),
which
enormously
hinders
development
of
nanodrugs.
Inspired
natural
merits
extracellular
vesicles,
we
therefore
developed
a
combined
"eat
me/don't
eat
me"
strategy
an
effort
to
achieve
MPS
escape
efficient
drug
delivery.
Methodologically,
cationized
mannan-modified
vesicles
derived
from
DC2.4
cells
were
administered
saturate
(eat
me
strategy).
Then,
nanocarriers
fused
CD47-enriched
exosomes
originated
human
serum
evade
phagocytosis
(don't
The
also
loaded
with
antitumor
drugs
functionalized
novel
homing
peptide
promote
tumour
tissue
accumulation
cancer
cell
concept
was
proven
vitro
as
evidenced
reduced
endocytosis
macrophages
enhanced
cells,
whereas
prolonged
circulation
time
increased
demonstrated
vivo.
Specially,
induced
123.53%
increase
distribution
compared
conventional
nanocarrier.
study
both
shed
light
on
overcoming
phagocytic
evasion
provided
for
significantly
improving
therapeutic
outcomes,
potentially
permitting
active
delivery
via
targeted
nanomedicines.
Frontiers in Cell and Developmental Biology,
Journal Year:
2021,
Volume and Issue:
9
Published: Sept. 20, 2021
Extracellular
vesicles
(EVs)
hold
great
promise
as
therapeutic
modalities
due
to
their
endogenous
characteristics,
however,
further
bioengineering
refinement
is
required
address
clinical
and
commercial
limitations.
Clinical
applications
of
EV-based
therapeutics
are
being
trialed
in
immunomodulation,
tissue
regeneration
recovery,
delivery
vectors
for
combination
therapies.
Native/biological
EVs
possess
diverse
properties
that
offer
stability
facilitate
crossing
biological
barriers
molecular
cargo
cells,
acting
a
form
intercellular
communication
regulate
function
phenotype.
Moreover,
important
components
paracrine
signaling
stem/progenitor
cell-based
therapies,
employed
standalone
can
be
used
drug
system.
Despite
remarkable
utility
native/biological
EVs,
they
improved
using
bio/engineering
approaches
potential.
engineered
harbor
specific
pharmaceutical
content,
enhance
stability,
modify
surface
epitopes
tropism
targeting
cells
tissues
vivo.
Limitations
currently
challenging
the
full
realization
include
scalability
standardization
generation,
characterization
design
regulation,
potency
assessment,
targeted
delivery.
The
fields'
utilization
advanced
technologies
(imaging,
quantitative
analyses,
multi-omics,
labeling/live-cell
reporters),
biocompatible
natural
sources
producing
(plants,
bacteria,
milk)
will
play
an
role
overcoming
these
Advancements
EV
engineering
methodologies
development
therapeutics,
revolutionizing
current
landscape.
